Format

Send to

Choose Destination
Nat Rev Drug Discov. 2014 Mar;13(3):197-216. doi: 10.1038/nrd4100.

REV-ERB and ROR nuclear receptors as drug targets.

Author information

1
Department of Molecular Therapeutics, The Scripps Research Institute, 130 Scripps Way, Jupiter, Florida 33458, USA.
2
Department of Pharmacological & Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, Missouri 63104, USA.

Abstract

The nuclear receptors REV-ERB (consisting of REV-ERBα and REV-ERBβ) and retinoic acid receptor-related orphan receptors (RORs; consisting of RORα, RORβ and RORγ) are involved in many physiological processes, including regulation of metabolism, development and immunity as well as the circadian rhythm. The recent characterization of endogenous ligands for these former orphan nuclear receptors has stimulated the development of synthetic ligands and opened up the possibility of targeting these receptors to treat several diseases, including diabetes, atherosclerosis, autoimmunity and cancer. This Review focuses on the latest developments in ROR and REV-ERB pharmacology indicating that these nuclear receptors are druggable targets and that ligands targeting these receptors may be useful in the treatment of several disorders.

PMID:
24577401
PMCID:
PMC4865262
DOI:
10.1038/nrd4100
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center